Focused On-demand Library for Pumilio homolog 1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We employ our advanced, specialised process to create targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q14671

UPID:

PUM1_HUMAN

Alternative names:

Alternative UPACC:

Q14671; A8K6W4; B4DG92; D3DPN3; E9PCJ0; Q53HH5; Q5VXY7; Q9HAN1

Background:

Pumilio homolog 1 (PUM1) is a sequence-specific RNA-binding protein, crucial for post-transcriptional regulation. It binds to the Pumilio Response Element on mRNA targets, leading to repression via mechanisms like deadenylation and miRNA accessibility. PUM1 plays a pivotal role in cell cycle entry, genomic stability, neuronal functions, and embryonic stem cell renewal.

Therapeutic significance:

Spinocerebellar ataxia 47, a disorder marked by incoordination and developmental disability, is linked to PUM1 gene variants. Understanding PUM1's role could unveil new therapeutic strategies for this and potentially other neurological conditions.